Frankfurt
06.06.25 | 15:29
1,718 Euro
-2,39 % -0,042
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | ADVICENNE: Advicenne met à disposition son Document d'Enregistrement Universel 2024 | 2 | Euronext | ||
| 29.04. | Advicenne 2024 Universal Registration Document Made Available | 206 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 423 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 366 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 385 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 452 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 157 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 410 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 428 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| 18.07.24 | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 372 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,600 | +1,93 % | Investor Woche: Nintendo launcht Switch 2, Tesla nach Musk-Trump-Drama im Sinkflug, EZB senkt Zinsen, Konjunkturdaten durchwachsen, Pfizer baut Stellen ab | Donald Trump und Elon Musk dominieren die Schlagzeilen: diese Woche durch das dramatisch vorgetragene Ende ihrer Männerfreundschaft. Dass Friedrich Merz im Oval Office war und die EZB die Zinsen senkte... ► Artikel lesen | |
| ABBVIE | 167,00 | +1,83 % | Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? | ||
| HAEMATO | 11,300 | +2,73 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
| HALEON | 4,850 | 0,00 % | Haleon PLC - Director/PDMR Shareholding | ||
| LIGAND PHARMACEUTICALS | 92,50 | +1,65 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,150 | +2,11 % | Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program | Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May... ► Artikel lesen | |
| ROYALTY PHARMA | 29,690 | +0,61 % | Dividendenbekanntmachungen (16.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADIDAS AG DE000A1EWWW0 - 2 EUR AF GRUPPEN ASA NO0003078107 5 NOK 0,4289 EUR AIXTRON SE DE000A0WMPJ6 - 0,15 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0... ► Artikel lesen | |
| TG THERAPEUTICS | 34,920 | +1,64 % | TG Therapeutics shares MS drug trial updates | ||
| EISAI | 23,910 | -1,52 % | Aktie von Eisai legt um 4,64 Prozent zu (25,46 €) | Im Plus liegt derzeit der Anteilsschein von Eisai . Das Wertpapier notiert gegenwärtig bei 25,46 Euro. Ein Kursplus von 4,64 Prozent steht gegenwärtig für das Wertpapier von Eisai zu Buche. Das Papier... ► Artikel lesen | |
| DR REDDYS | 13,800 | 0,00 % | Dr. Reddy's Laboratories Ltd.: Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE:... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 74,20 | +3,34 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,057 | 0,00 % | BetterLife Pharma Inc. - 20-F, Annual and transition report of foreign private issuers | ||
| ENTOURAGE HEALTH | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2025ISIN NameCA2938611001 ENTOURAGE... ► Artikel lesen | |
| KYOWA KIRIN | 14,600 | 0,00 % | Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting | - CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups... ► Artikel lesen | |
| IGC PHARMA | 0,280 | +5,26 % | IGC Pharma, Inc.: IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market | POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.